Peptide Profile

BPC-157

Body Protection Compound-157 is one of the most extensively studied healing peptides, demonstrating remarkable regenerative properties across multiple organ systems in preclinical research.

25 min read · Last updated March 2026 · 100+ research citations

15
Amino Acids
1419
Daltons
100+
Studies
View ResearchDosage Guide

Research Use Only: BPC-157 is not approved by the FDA or any regulatory agency for human therapeutic use. All information presented here is based on preclinical research and is intended for educational purposes only.

Key Takeaways

Origin
Synthetic 15-amino acid peptide derived from human gastric juice protein
Research Status
Extensively studied in animal models; no completed human clinical trials
Primary Research Areas
GI healing, tendon/ligament repair, muscle recovery, neuroprotection
Mechanism
NO system modulation, growth factor upregulation, angiogenesis, FAK-paxillin pathway
Stability
Unusual stability in gastric acid - allows oral administration
Research Dosages
Animal studies: 10-50 mcg/kg body weight
Administration
Subcutaneous, intramuscular, oral, and topical routes studied
Safety Profile
Well-tolerated in animal studies with minimal adverse effects
Regulatory Status
Not FDA approved; classified as research chemical

Overview

What is BPC-157?

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a larger protective protein naturally occurring in human gastric juice, which plays a crucial role in maintaining the integrity of the gastrointestinal tract.

Discovery and Origins

The discovery of BPC-157 emerged from research conducted at the University of Zagreb in Croatia during the late 1980s and early 1990s. Researchers led by Dr. Predrag Sikiric observed that certain peptide fractions isolated from gastric juice possessed remarkable protective properties against various forms of tissue damage.

The gastric juice, produced by the stomach lining, contains numerous protective factors that help maintain mucosal integrity despite constant exposure to hydrochloric acid and digestive enzymes. Among these factors, researchers identified a specific protein sequence that demonstrated exceptional cytoprotective capabilities.

BPC-157 represents a partial sequence of this larger parent protein, specifically engineered to retain and potentially enhance the protective properties of the full compound. The "157" designation refers to its specific peptide sequence identification within the research nomenclature.

Natural Occurrence and Synthesis

While the parent protein from which BPC-157 is derived occurs naturally in gastric secretions, the specific 15-amino acid sequence that constitutes BPC-157 is produced synthetically for research purposes. The natural concentration of this sequence in gastric juice is extremely low, measured in nanogram quantities, necessitating synthetic production for research applications.

The synthetic production of BPC-157 involves solid-phase peptide synthesis (SPPS), a standard method for producing research-grade peptides. This process allows for the creation of highly pure compounds suitable for scientific investigation.

Historical Research Volume
100+
peer-reviewed publications

Since initial characterization, spanning multiple organ systems and pathological conditions

Chemistry

Molecular Structure & Properties

Amino Acid Sequence

N
G
Glycine
Position 1
1
E
Glutamic Acid
Position 2
2
P
Proline
Position 3
3
P
Proline
Position 4
4
P
Proline
Position 5
5
G
Glycine
Position 6
6
K
Lysine
Position 7
7
P
Proline
Position 8
8
A
Alanine
Position 9
9
D
Aspartic Acid
Position 10
10
D
Aspartic Acid
Position 11
11
A
Alanine
Position 12
12
G
Glycine
Position 13
13
L
Leucine
Position 14
14
V
Valine
Position 15
15
C
Nonpolar
Polar
Acidic
Basic
NN-terminus
CC-terminus
Full notation: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

This sequence does not correspond to any other known native peptide in human body databases, making BPC-157 a unique synthetic construct derived from, but distinct from, its parent protein.

Molecular Formula
C₆₂H₉₈N₁₆O₂₂
Molecular Weight
1419.53 g/mol
CAS Number
137525-51-0
Purity (Research)
>98% HPLC

Physical Properties

AppearanceWhite to off-white powder
SolubilityFreely soluble in water and aqueous buffers
Storage (Lyophilized)Stable at -20°C for extended periods
Storage (Reconstituted)Refrigerate, use within specified timeframes

Stability Characteristics

One of the most notable properties of BPC-157 is its exceptional stability compared to other peptides, particularly in acidic environments.

Acid Stability
Maintains structural integrity in pH 1-2 conditions that would denature most peptides
Heat Stability
Relative stability at elevated temperatures
Proteolytic Resistance
Resists degradation by common proteolytic enzymes - enables oral bioavailability

Variants and Forms

BPC-157 (Free Base)
The native peptide sequence as described above
BPC-157 Acetate Salt
Most commonly used form - improved stability and solubility

Both forms demonstrate similar biological activities in research settings.

Science

How BPC-157 Works

The mechanisms through which BPC-157 exerts its effects are complex and involve multiple interconnected pathways

Nitric Oxide System Modulation

The nitric oxide system plays a central role in BPC-157's mechanism. NO is a crucial signaling molecule involved in vasodilation, angiogenesis, immune function, and tissue repair.

NO Synthase Interaction:
  • Endothelial NOS (eNOS)
  • Neuronal NOS (nNOS)
  • Inducible NOS (iNOS)

BPC-157 can either upregulate or downregulate NO production depending on tissue context and pathological state—a bidirectional modulation that contributes to its protective effects.

Growth Factor Upregulation

BPC-157 has been shown to increase expression of several growth factors critical for tissue repair and regeneration.

VEGF
Essential for angiogenesis and new blood vessel formation
EGF
Contributes to epithelial cell proliferation and wound healing
TGF-β
Plays roles in collagen synthesis and tissue remodeling
HGF
Implications for liver regeneration and multi-organ repair

Angiogenesis Promotion

Enhanced blood vessel formation observed in wound healing, tendon repair, muscle injury, and gastric ulcer healing studies.

FAK-Paxillin Pathway

Activates focal adhesion kinase pathway crucial for cell migration, adhesion, and tissue organization.

Dopamine System

Demonstrated interactions showing protective effects against dopaminergic neurotoxins and receptor modulation.

Cytoprotection

Stabilizes cellular membranes and reduces oxidative stress through heat shock proteins and antioxidant enzymes.

Additional Mechanisms Under Investigation

GABA System

Effects on GABAergic neurotransmission may contribute to observed anxiolytic and neuroprotective properties

Serotonin System

Modulation of serotonergic pathways with potential implications for mood and GI function

Opioid System

Some research indicates interactions that may relate to pain modulation

Evidence

Research Overview

BPC-157 has been investigated across numerous organ systems and pathological conditions

🔬

Gastrointestinal Research

40+ studies

The gastrointestinal tract represents the most extensively studied application of BPC-157, consistent with its origin from gastric juice.

Gastric Ulcer Studies
Multiple rat studies demonstrated accelerated healing with increased mucus secretion, angiogenesis, and epithelial regeneration
Inflammatory Bowel Disease
TNBS-induced colitis models showed anti-inflammatory effects and accelerated mucosal healing
Esophageal Injury
Protective effects against acid, alkali, and thermal injury with enhanced barrier function
NSAID-Induced Damage
Protection against gastric and intestinal lesions through prostaglandin-independent mechanisms
💪

Tendon, Ligament & Muscle Research

30+ studies

One of the most promising research applications, showing accelerated healing across multiple injury types.

Achilles Tendon
Accelerated functional recovery, improved tendon-to-bone healing, enhanced collagen organization, increased tensile strength
MCL & Rotator Cuff
Faster healing with improved collagen fiber alignment and enhanced biomechanical properties
Muscle Crush Injury
Reduced fiber damage, accelerated satellite cell activation, improved recovery, reduced fibrosis
Mechanism
Increased VEGF, FAK-paxillin activation, improved collagen type I synthesis, better fiber alignment
🧠

Neurological Research

20+ studies
Dopaminergic Protection
Protection against MPTP and 6-OHDA neurotoxins with preserved dopamine levels and reduced motor impairment
Peripheral Nerve Injury
Accelerated regeneration, improved functional recovery, enhanced remyelination in sciatic nerve models
Traumatic Brain Injury
Reduced edema, improved behavioral outcomes, decreased neuroinflammation in animal models
Serotonin Modulation
Potential to counteract serotonin-depleting drugs and modulate receptor sensitivity
❤️

Cardiovascular Research

15+ studies
Blood Pressure
Bidirectional modulation - counteracts both hypertensive and hypotensive agents through NO system
Cardiac Protection
Reduced infarct size, improved cardiac function, enhanced peri-infarct angiogenesis
Antiarrhythmic Effects
Potential effects observed in drug-induced arrhythmia models
Vascular Healing
Improved anastomosis healing and patency rates similar to intestinal findings
🦴

Bone Healing Research

10+ studies
Fracture Healing
Enhanced callus formation, improved BMD, accelerated radiographic healing
Segmental Defects
Improved healing parameters in larger bone defect models
Pseudoarthrosis
Some improvement in non-healing fracture models

Applications

Potential Benefits

Based on preclinical research. Human efficacy has not been established through clinical trials.

🔬

Gastrointestinal Protection

  • Acceleration of gastric and intestinal ulcer healing
  • Protection against NSAID-induced damage
  • Anti-inflammatory effects in bowel disease models
  • Enhanced mucosal barrier function
💪

Musculoskeletal Repair

  • Acceleration of tendon and ligament healing
  • Improved muscle regeneration following damage
  • Enhanced bone healing in fracture models
  • Better tissue organization and reduced fibrosis
🧠

Neuroprotection

  • Protection against neurotoxin-induced damage
  • Enhanced peripheral nerve regeneration
  • Potential CNS protective effects
  • Modulation of neurotransmitter systems
❤️

Cardiovascular Effects

  • Cardioprotection in ischemia models
  • Blood pressure modulation
  • Enhanced vascular healing
  • Potential antiarrhythmic properties

Important Caveats

  • All benefits based on animal and in vitro research
  • Human efficacy has not been established
  • Translation from animal models not guaranteed
  • Optimal dosing for humans is unknown
  • Long-term safety in humans not evaluated
  • Not approved for any medical condition

Protocols

Dosage Information

Derived from published animal research. These are not human dosing recommendations.

Research Protocol Dosages

10 mcg/kg
Lower range
50 mcg/kg
Most commonly used
100-250 mcg/kg
Higher range
Systemic Administration (Injection)
  • • Typical range: 10-50 mcg/kg body weight
  • • Most common: 10 mcg/kg IP or SC
  • • Higher doses (250 mcg/kg) in specific protocols
Local/Perilesional Injection
  • • Often used near injury sites
  • • Typical range: 2-10 mcg applied locally
  • • Sometimes combined with systemic administration

Duration of Treatment

Acute studiesSingle dose or several days
Subchronic studies1-4 weeks
Chronic studiesUp to several months

Critical Notes

  • No established human dosage - these are animal research doses only
  • Direct extrapolation from animals to humans is not scientifically valid
  • Individual variation in response is expected
  • Not medical advice - consult qualified researchers

Methods

Administration Routes

Subcutaneous

Between skin and muscle

  • Relatively simple technique
  • Slower absorption than IM
  • Common site: abdominal region
  • Used for both local and systemic effects

Intramuscular

Directly into muscle tissue

  • Faster absorption than SC
  • Higher local concentrations
  • Used for muscle-specific effects
  • May provide systemic distribution

Intraperitoneal

Into abdominal cavity

  • Rapid absorption
  • Standard for rodent studies
  • Allows systemic distribution
  • Not typically used in humans

Oral

Taken by mouth

  • Non-invasive route
  • BPC-157's acid stability enables this
  • May require higher doses
  • Relevant for GI applications
Unique to BPC-157

Topical

Applied to skin surface

  • Local delivery to wounds
  • May use carriers or gels
  • Limited systemic absorption
  • Wound healing research focus

Local/Perilesional

Near injury site

  • High local concentration
  • Lower systemic exposure
  • Used in tendon/muscle studies
  • Enhanced local effects reported

Safety

Side Effects & Safety Profile

Animal Study Findings

General Tolerability

Good tolerability in the majority of published studies with minimal reported adverse effects

Acute Toxicity

No lethal dose (LD50) established, suggesting wide safety margin. High-dose studies show no significant acute toxicity

Behavioral Effects

No sedation or motor impairment at standard doses. Some anxiolytic effects without sedation

Physiological Parameters

No significant effects on body weight, food/water intake, or standard blood chemistry in available studies

Theoretical Concerns & Limitations

Cancer/Tumor Growth

Angiogenesis and growth factor promotion raises theoretical concerns. No direct evidence of tumor promotion, but limited long-term studies.

Immune System

Potential immunomodulatory effects not fully characterized. Long-term immune function effects unknown.

Drug Interactions

Potential interactions with cardiovascular meds, NO system drugs. Limited systematic interaction studies.

Human Data Gap

No completed human clinical trials. Human safety profile not established. Long-term effects unknown.

Contraindications

Who Should NOT Use BPC-157

Absolute Contraindications

Pregnancy and Lactation
No reproductive toxicity studies. Effects on fetal development unknown.
Children and Adolescents
Effects on development, growth, and hormonal systems not studied.
Active Cancer or Cancer History
Angiogenic and growth-promoting properties raise concerns about tumor stimulation.

Relative Contraindications (Caution)

Uncontrolled hypertension
Recent myocardial infarction
Severe heart failure
Anticoagulant use
Active autoimmune disease
Immunocompromised states
Liver or kidney disease
Bleeding disorders
Recent surgery
Severe psychiatric conditions
Psychotropic medication use

Comparisons

BPC-157 vs Other Peptides

BPC-157 vs TB-500 (Thymosin Beta-4)

CharacteristicBPC-157TB-500
OriginDerived from gastric juiceNaturally in most tissues
Size15 amino acids43 amino acids
Primary FocusGI healing, tendon repairWound healing, cardiac
MechanismNO system, growth factorsActin sequestration
Oral Stability✓ Acid-stable✗ Not orally active

Some researchers investigate combinations ("Wolverine Stack"), hypothesizing synergistic effects through different mechanisms.

vs GHK-Cu (Copper Peptide)
  • • GHK-Cu: Tripeptide with copper ion
  • • Primarily topical/cosmetic applications
  • • BPC-157: Broader systemic applications
  • • Different mechanisms of action
vs IGF-1 LR3
  • • IGF-1: Direct anabolic/growth effects
  • • BPC-157: Multiple indirect pathways
  • • Different risk profiles
  • • Different primary applications

Unique Characteristics of BPC-157

💊
Oral Bioavailability
Rare among peptides
🎯
Multisystem Effects
Across numerous organs
⚡
NO Modulation
Bidirectional regulation
🛡️
Safety Profile
Well-tolerated in studies

FAQ

Frequently Asked Questions

Critical Analysis

Current Research Limitations

Lack of Human Trials

No completed Phase III human clinical trials. Human efficacy and safety not established. Optimal dosing unknown.

Geographic Concentration

Majority of research from University of Zagreb group. Limited independent replication by other labs worldwide.

Study Quality Variations

Variable study designs and outcome measures. Limited standardization. Sample sizes typical for animal research.

Publication Bias

Negative or null results may be underreported. Need for systematic reviews and meta-analyses.

Mechanism Understanding

Multiple proposed mechanisms not fully integrated. Dose-response relationships not fully characterized.

Long-Term Safety

Most studies short-term. Chronic effects poorly characterized. Carcinogenicity studies limited.

Related Compounds & Content

Peptide

TB-500

Wound healing & tissue repair

Peptide

GHK-Cu

Copper peptide research

Guide

Wolverine Stack Guide

BPC-157 + TB-500 combination

Guide

Reconstitution Guide

How to prepare peptides

References

  1. Sikiric P, et al. (1994). Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model. Dig Dis Sci, 39(8):1641-1649.
  2. Sikiric P, et al. (1999). Dopamine agonists and brain dopamine system. J Physiol Paris, 93(6):505-512.
  3. Sikiric P, et al. (2003). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem, 10(2):175-186.
  4. Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res, 21(6):976-983.
  5. Krivic A, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res, 24(5):982-989.
  6. Sikiric P, et al. (2010). Brain-gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol, 8(3):207-231.
  7. Gjurasin M, et al. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept, 160(1-3):33-41.
  8. Pevec D, et al. (2010). Impact of pentadecapeptide BPC 157 on muscle healing. Med Sci Monit, 16(3):BR81-88.
  9. Sikiric P, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in GI tract. Curr Pharm Des, 17(16):1612-1632.
  10. Seiwerth S, et al. (2012). BPC 157 and standard angiogenic growth factors. Curr Pharm Des, 18(36):5867-5880.
  11. Tkalcevic VI, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization. Eur J Pharmacol, 570(1-3):212-221.
  12. Hsieh MJ, et al. (2017). Healing and anti-inflammatory effects in corneal epithelial wounds. Life Sci, 176:44-49.
  13. Chang CH, et al. (2014). The promoting effect on tendon healing involves outgrowth, survival, migration. J Appl Physiol, 117(7):722-730.
  14. Sikiric P, et al. (2013). Counteraction of short bowel syndrome. Front Gastrointest Res, 30:108-120.
  15. Sikiric P, et al. (2016). Stable gastric pentadecapeptide BPC 157 in IBD trials. Curr Pharm Des, 22(9):1081-1090.
  16. Vukojevic J, et al. (2018). Pentadecapeptide BPC 157 and CNS. Neural Regen Res, 13(12):2063-2065.
  17. Sikiric P, et al. (2017). Brain-gut axis and BPC 157: update and advances. Curr Neuropharmacol, 15(1):58-76.
  18. Xue XC, et al. (2004). BPC 157 inhibits melanoma growth. Anticancer Res, 24(2B):953-959.
  19. Sikiric P, et al. (2006). The gastric pentadecapeptide BPC 157 in cytoprotection. Dig Dis, 24(1-2):148-154.
  20. Cesarec V, et al. (2013). Pentadecapeptide BPC 157 and esophagocutaneous fistula healing. Eur J Pharmacol, 701(1-3):203-212.
  21. Sikiric P, et al. (2014). Peripheral nerve regeneration. Neural Regen Res, 9(17):1662-1664.
  22. Klicek R, et al. (2013). Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis. J Physiol Pharmacol, 64(5):597-612.
  23. Sikiric P, et al. (2018). Pentadecapeptide BPC 157 and wound healing in rats. Front Pharmacol, 9:1-12.
  24. Drmic D, et al. (2018). Counteraction of perforated cecum lesions. World J Gastroenterol, 24(44):5026-5042.
  25. Sikiric P, et al. (2020). Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol, 11:569994.
  26. Seiwerth S, et al. (2018). BPC 157 and blood vessels. Curr Pharm Des, 24(36):4285-4299.
  27. Vukojević J, et al. (2020). Pentadecapeptide BPC 157 and cardiovascular system. Curr Pharm Des, 26(25):2934-2949.
  28. Sikiric P, et al. (2021). Pentadecapeptide BPC 157 resolves Pringle maneuver in rats. World J Gastroenterol, 27(10):915-938.

Disclaimer: This pillar page is intended for educational and research purposes only. BPC-157 is a research compound that has not been approved by the FDA for human use. Nothing in this document should be construed as medical advice or a recommendation for use. Always consult with qualified professionals and follow all applicable laws and regulations.

Last updated: March 2026 · Reviewed by: Scientific Aminos Editorial Board

B2B Wholesale

Order BPC-157 Wholesale

US-manufactured, HPLC verified. Available for distributors, telehealth providers, clinics, and research institutions.

View ProductApply for Account